Investing Center Preview – Manage your investments and watch your net worth grow.
BMY:NYSE – Large Cap Stock (Drug Manufacturers)
Bristol-Myers Squibb Co – BMY Stock Overview
| Last Price | Today's Change | 52-Week Range | Trading Volume |
|---|---|---|---|
| 53.74 | 0.00 (0.00%) | 39.35 - 63.33 | 69.0 (Below Avg) |
Market data as of 4:00PM 04/09/25. Quotes are delayed by at least 15 min.
Overview - BMY
| Open | -- |
|---|---|
| Previous Close | 53.74 |
| Day's Range | -- - -- |
| Market Cap | 109.3B |
| Avg Volume (10 Day) | 13.4M |
| Price/Earnings (Trailing 12 Mo.) | -- |
| Earnings Per Share (Trailing 12 Mo.) | 0.552 |
| Dividend Yield | 0.62 (4.61%) |
One-Click Scorecard - BMY
These seven metrics are a snap to calculate, thanks to Quicken.com's One-Click Scorecard. Our goal with this tool is to help you evaluate potential investment candidates and eliminate those equities that aren't up to snuff. One-Click Scorecard won't do all the homework necessary for you to reach a decision, but it will help you develop a list of quality stocks to watch and study further.
| Performed well consistently? | Fail |
|---|---|
| Avoids excess debt? | Pass |
| Converting sales to profits? | Fail |
| Shareholder's money handled rationally? | Pass |
| Increased shareholder value? | Fail |
| Consistently increased owner earnings? | Pass |
| Sells at 25% discount to intrinsic value? | Pass |
These eight metrics are a snap to calculate, thanks to Quicken.com's One-Click Scorecard. Our goal with this tool is to help you evaluate potential investment candidates and eliminate those equities that aren't up to snuff. One-Click Scorecard won't do all the homework necessary for you to reach a decision, but it will help you develop a list of quality stocks to watch and study further.
| Pays a cash dividend? | Pass |
|---|---|
| Room to increase dividends? | Fail |
| Increased earnings over time? | Pass |
| Borrows within reasonable limits? | Fail |
| Stock is undervalued? | Fail |
| Have investors caught on? | Fail |
| Has support of institutional investors? | Pass |
| Has sufficient liquidity? | Pass |
Latest Headlines - BMY
U.S. Food and Drug Administration Approves Opdivo® (nivolumab) plus Yervoy® (ipilimumab) as a Treatment for Patients with Previously Untreated Microsatellite Instability-High or Mismatch Repair Deficient Unresectable or Metastatic Colorectal Cancer¹
Business Wire - Tuesday 04/08/2025 3:36 PM ET
Viz.ai Wins 2025 Edison Award™ for Machine Learning Innovation for the Third Consecutive Year
Business Wire - Friday 04/04/2025 8:24 AM ET
Bristol Myers Squibb Receives Positive CHMP Opinion for Perioperative Regimen of Neoadjuvant Opdivo® (nivolumab) and Chemotherapy Followed by Surgery and Adjuvant Opdivo for Resectable Non-Small Cell Lung Cancer in Patients with Tumor Cell PD-L1...
Business Wire - Friday 03/28/2025 8:53 AM ET
Bristol Myers Squibb Receives Positive CHMP Opinion for the Subcutaneous Formulation of Opdivo® (nivolumab) Across Multiple Solid Tumor Indications
Business Wire - Friday 03/28/2025 8:00 AM ET
Four New Studies Demonstrate that Viz.ai Finds New Patients with Hypertrophic Cardiomyopathy Earlier When Embedded into the Clinical Workflow
Business Wire - Wednesday 03/26/2025 9:24 AM ET
Cardurion Pharmaceuticals Appoints Karen Lewis as Chief People Officer
Business Wire - Thursday 03/20/2025 8:00 AM ET
Bristol Myers Squibb Receives Approval from the European Commission to Expand Use of CAR T Cell Therapy Breyanzi for Relapsed or Refractory Follicular Lymphoma
Business Wire - Friday 03/14/2025 6:59 AM ET
Bristol Myers Squibb to Report Results for First Quarter 2025 on April 24, 2025
Business Wire - Thursday 03/13/2025 6:59 AM ET
Industry Position - BMY
| BMY | Industry Range | |
|---|---|---|
| Revenue Growth (1yr) | 7.32% | |
| Net Income Growth (1yr) | -- | |
| Total Debt/Equity | 3.13 | |
| LT Debt/Equity | 3.00 | |
| Earnings Yield | -- | |
| Price/Sales | 2.32 |
Competitors - BMY
| Company | Last | Change |
|---|---|---|
| 4878.00 | -0.12% | |
| 86.76 | -6.89% | |
| 206.00 | +0.06% | |
| 193.50 | -7.86% | |
| Pfizer Inc | 22.49 | 0.00% |
Data is delayed by at least 15 min.